

Herantis Pharma Announces Formation of New Scientific Advisory Board with Dr. Anders Gersel Pedersen as Chairman

Noted international pharmaceutical industry expert Dr. Anders Gersel Pedersen is announced to new Scientific Advisory Board as Chairman

Herantis Pharma Plc, Press Release, 14 September 2021 at 9:00 EEST

Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, today announced that it has named eminent international pharmaceutical expert Dr. Anders Gersel Pedersen to its new scientific advisory board as Chairman. Dr. Pedersen brings impeccable experience, expertise and track record in the pharmaceutical industry and the development of new drugs for CNS diseases.

“We are delighted to welcome an expert of the caliber of Dr Pedersen to our SAB as Chairman. I have no doubt that Herantis will benefit enormously from Anders experience and leadership,” said Dr. Craig Cook, CEO. “His input will be invaluable as we continue to shape our xCDNF and rhCDNF programs and accelerate development towards the clinic. Anders joins the SAB at an exciting time for the company and we are very pleased to have such an esteemed expert working with our own team to endorse, challenge, validate and guide our programs.”

Dr. Pedersen spent nineteen years at Lundbeck from 2000 to 2019, seven years of which he lead the R&D organization as Executive Vice President of Research & Development from 2013 – 2019. Anders is currently a member of the board of Hansa Biopharma, where he also is Chairman of the scientific committee. He has served since 2003 on the board of Genmab (previously as Chairman), a leading biotechnology company focused on development and specialisation of antibody products and he has served since 2009 on the board of Bavarian Nordic (currently as Deputy Chairman), a biotechnology company specialized in vaccines. In November 2020, he joined Aelis Farma as Chairman of the Board. He previously also served for more than 10 years (2000-2011) on the board of TopoTarget and for twelve years on the board of ALK-Abelio (2005-2018). Other notable positions included working for Eli Lilly for eleven years as a director overseeing worldwide clinical research in oncology. Dr. Pedersen received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School. He is a member of the Danish Society of Internal Medicine.

“I am very excited to be joining Herantis SAB and look forward to contributing to the critical thinking for the further development of their promising CNS assets for treatment of neurodegenerative diseases such as Parkinsons,” said Dr. Gersel Pedersen. “The company is well positioned with their their ground breaking science coupled with a talented team, so I very much I look forward to being involved in the next chapter of the company’s growth”

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson's Disease, Alzheimer's and other diseases. CDNF (a biological protein) is Herantis' lead program and a clinical stage asset; and xCDNF (a synthetic peptide version of CDNF) is Herantis' follow-on program. CDNF is a natural protein that occurs naturally in the body whose natural role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. Both CDNF and xCDNF, via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson's and other neurodegenerative diseases with a significant therapeutic impact on the quality of patients' lives.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit <https://www.herantis.com>